Mercy BioAnalytics

Mercy BioAnalytics' mission is to alleviate suffering and save lives through the early detection of cancer. The company's patented Mercy Halo™ liquid biopsy platform utilizes biomarker co-localization to examine highly enriched blood-based extracellular vesicles carrying unique cancer signatures from their parent cells. The Mercy Halo™ platform is designed to detect the most treatable Stage I cancers and improve the quality of life for cancer patients and their families. Mercy’s initial focus is on the early detection of ovarian and lung cancer.